GlassScriptPhysician profile
Marcos Manon
NPI 1174603591
$684.35
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $31.81 · 2021: $169 · 2022: $140.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $181.11 | 2019-2022 | |
| Amgen INC. | $144.27 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $137.82 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $67.70 | 2021-2022 | |
| Akebia Therapeutics INC | $33.96 | 2022 | |
| Nxstage Medical, INC. | $33.23 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $32.90 | 2021 | |
| Genentech USA, INC. | $19.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.24 | 2022 | |
| Vifor Pharma, INC. | $16.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Manon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.